AKBA

Akebia Therapeutics Inc

Add to Watchlist

Advanced Chart

3.320

-0.03(-0.896%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.400

Open

3.360

VWAP

3.32

Vol

3.06M

Mkt Cap

880.28M

Low

3.290

Amount

10.17M

EV/EBITDA(TTM)

34.19

Total Shares

209.60M

797.99M

EV/OCF(TTM)

P/S(TTM)

3.87

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

60.75M

+5.96%

48.53M

+4.37%

48.70M

+30.11%

Estimates Revision

The market is revising Upward the revenue expectations for Akebia Therapeutics, Inc. (AKBA) for FY2025, with the revenue forecasts being adjusted by 1.17% over the past three months. During the same period, the stock price has changed by 33.87%.

Revenue Estimates for FY2025

Revise Upward

+1.17%

In Past 3 Month

Stock Price

Go Up

+33.87%

In Past 3 Month

3 Analyst Rating

110.84% Upside

Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

110.84% Upside

Current: 3.320

Low

6.00

Averages

7.00

High

8.00

110.84% Upside

Current: 3.320

Low

6.00

Averages

7.00

High

8.00

H.C. Wainwright

Matthew Caufield

initiated

2025-06-04

Reason

H.C. Wainwright

Matthew Caufield

Price Target

2025-06-04

initiated

Reason

H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia with a Buy rating and $8 price target. The company's approved product Vafseo indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months, continues to gain uptake among dialysis organizations, the analyst tells investors in a research note. The firm believes the ongoing Vafseo launch can offset generic impact on the company's other approved product Auryxia, which has focused commercially on the hyperphosphatemia indication.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-04-04

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-04-04

Reiterates

Strong Buy

Reason

Jefferies

Roger Song

Strong Buy

Initiates

2025-04-01

Reason

Jefferies

Roger Song

Price Target

2025-04-01

Initiates

Strong Buy

Reason

Jefferies initiated coverage of Akebia with a Buy rating and $6 price target. Akebia is a commercial-stage biotech specializing in kidney disease, the analyst tells investors in a research note. The company's initial U.S. launch of Vafseo under the Transitional Drug Add-on Payment Adjustment is looking encouraging with potential durable sales post the TDAPA, the analyst tells investors in a research note. Jefferies says the company has a few early pipeline products with upside potential.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-03-14

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-03-14

Reiterates

Strong Buy

Reason

Piper Sandler

Allison Bratzel

Buy

Maintains

$4 → $6

2025-03-14

Reason

Piper Sandler

Allison Bratzel

Price Target

$4 → $6

2025-03-14

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Akebia to $6 from $4 and keeps an Overweight rating on the shares. The firm says it remains a buyer of Akebia shares following Q4 reporting, which included a look at Vafseo launch progress that Piper finds encouraging. The firm thinks the stock reaction is misplaced given its view that the Vafseo launch is poised to exceed expectations, with Q1 2025 revenue expected to be $10M-$11M, essentially doubling consensus and PSC estimates.

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$7.5

2025-01-23

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$7.5

2025-01-23

Reiterates

Strong Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Akebia Therapeutics Inc (AKBA.O) is -36.49, compared to its 5-year average forward P/E of -5.33. For a more detailed relative valuation and DCF analysis to assess Akebia Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.33

Current PE

-36.49

Overvalued PE

2.40

Undervalued PE

-13.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.14

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.32

Undervalued EV/EBITDA

-2.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

1.76

Current PS

3.85

Overvalued PS

2.88

Undervalued PS

0.64

Financials

Annual

Quarterly

FY2025Q2

YoY :

+43.13%

62.47M

Total Revenue

FY2025Q2

YoY :

-270.08%

13.99M

Operating Profit

FY2025Q2

YoY :

-102.88%

247.00K

Net Income after Tax

FY2025Q2

YoY :

-100.00%

0.00

EPS - Diluted

FY2025Q2

YoY :

-320.10%

22.22M

Free Cash Flow

FY2025Q2

YoY :

+36.77%

82.53

Gross Profit Margin - %

FY2025Q2

YoY :

-94.41%

-1.25

FCF Margin - %

FY2025Q2

YoY :

-102.03%

0.40

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1879.81% over the last month.

Sold

0-3

Months

258.8K

USD

3-6

Months

13.1K

USD

6-9

Months

589.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 1879.81% over the last month.

Sold

0-3

Months

258.8K

USD

3-6

Months

13.1K

USD

6-9

Months

589.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AKBA News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

07:20:25

Akebia reports Q2 EPS 0c vs (4c) last year

2025-08-04 (ET)

2025-08-04

08:14:07

Akebia initiates post-marketing study to identify benefits of Vafseo

2025-06-04 (ET)

2025-06-04

08:02:58

Akebia announces JASN published analysis from vadadustat phase 3 program

News

9.5

08-07SeekingAlpha

Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches

5.0

06-29Yahoo Finance

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees

1.0

05-27Newsfilter

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

People Also Watch

EQV Ventures Acquisition Corp

AA Mission Acquisition Corp

Pacific Biosciences of California Inc

Central Garden & Pet Co

SIGA Technologies Inc

FAQ

What is Akebia Therapeutics Inc (AKBA) stock price today?

The current price of AKBA is 3.32 USD — it has decreased -0.9 % in the last trading day.

AKBA

Get winning stock picks in minutes

Market Estimates

Get winning stock picks in minutes

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AKBA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Akebia Therapeutics Inc (AKBA) stock price today?

What is Akebia Therapeutics Inc (AKBA)'s business?

What is the price predicton of AKBA Stock?

What is Akebia Therapeutics Inc (AKBA)'s revenue for the last quarter?

What is Akebia Therapeutics Inc (AKBA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Akebia Therapeutics Inc (AKBA)'s fundamentals?

How many employees does Akebia Therapeutics Inc (AKBA). have?

What is Akebia Therapeutics Inc (AKBA) market cap?